Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

A Novel Enediynyl Peptide Inhibitor of Furin That Blocks Processing of proPDGF-A, B and proVEGF-C

  • Ajoy Basak ,

    Affiliation Chronic Diseases Program, Regional Protein Chemistry Center, Ottawa Hospital Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottowa, Ottawa, Canada

  • Abdel-Majid Khatib,

    Affiliations INSERM, UMRS940, Equipe AVENIR. Institut de Génétique Moléculaire, Hospital St-Louis, Paris, France, Université Paris 7, Paris, France

  • Dayani Mohottalage,

    Affiliation Chronic Diseases Program, Regional Protein Chemistry Center, Ottawa Hospital Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottowa, Ottawa, Canada

  • Sarmistha Basak,

    Affiliation Chronic Diseases Program, Regional Protein Chemistry Center, Ottawa Hospital Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottowa, Ottawa, Canada

  • Maria Kolajova,

    Affiliation Chronic Diseases Program, Regional Protein Chemistry Center, Ottawa Hospital Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottowa, Ottawa, Canada

  • Subhendu Sekhar Bag,

    Affiliations Department of Chemistry, Indian Institute of Technology, Kharagpur, West Bengal, India, Department of Chemistry, Indian Institute of Technology, Guwahati, Assam, India

  • Amit Basak

    Affiliation Department of Chemistry, Indian Institute of Technology, Kharagpur, West Bengal, India



Furin represents a crucial member of secretory mammalian subtilase, the Proprotein Convertase (PC) or Proprotein Convertase Subtilisin/Kexin (PCSK) superfamily. It has been linked to cancer, tumorgenesis, viral and bacterial pathogenesis. As a result it is considered a major target for intervention of these diseases.

Methodology/Principal Findings

Herein, we report, for the first time, the synthesis and biological evaluation of a newly designed potent furin inhibitor that contains a highly reactive beta-turn inducing and radical generating “enediynyl amino acid” (Eda) moiety. “Eda” was inserted between P1 and P1′ residues of hfurin98–112 peptide, derived from the primary cleavage site of furin's own prodomain. The resulting hexadecapeptide derivative inhibited furin in vitro with IC50 ∼40 nM when measured against the fluorogenic substrate Boc-RVRR-MCA. It also inhibited furin-mediated cleavage of a fluorogenic peptide derived from hSARS-CoV spike protein with IC50 ∼193 nM. Additionally it also blocked furin-processing of growth factors proPDGF-A, B and VEGF-C that are linked to tumor genesis and cancer. Circular dichroism study showed that this inhibitor displayed a predominantly beta-turn structure while western blots confirmed its ability to protect furin protein from self degradation.


These findings imply its potential as a therapeutic agent for intervention of cancer and other furin-associated diseases.


Furin is a crucial member of Ca+2-dependent mammalian subtilases collectively known as Proprotein Convertases (PCs) or Proprotein Convertase Subtilisin/Kexins (PCSKs). This membrane bound type 1 protease is responsible for tissue-specific endoproteolytic cleavage of a large variety of inactive protein precursors at the general sequence motif (K/R)-(X)n-(R) ↓ (where n  = 0, 2, 4 or 6 and X is usually any amino acid other than Cys), leading to functionally active secretory proteins and polypeptides [1][3]. Among the known furin substrates are the precursors of hormones, neuropeptides, growth factors, adhesion molecules, receptors, surface proteins, viral glycoproteins and bacterial toxins [2]. Based on above findings and accumulated studies in the literature, furin has been strongly linked to tumorgenesis, hormonal diseases, neurological dementia and a variety of infectious diseases caused by ebola, avian, Hong Kong, HIV, human SARS corona viruses as well as bacterial pathogenesis due to anthrax toxin, aerolysin etc [4][9]. Owing to these results, this enzyme is considered as a potential prognostic factor for several diseases. Therefore many researchers including us became interested in the development of potent and specific furin inhibitors that may possess important biochemical, clinical and therapeutic applications. Until now, several macromolecules and small compound furin inhibitors have been reported in the literature [reviewed in 10,11]. While all macromolecule furin inhibitors are of protein types either endogenous or biologically engineered, the small molecule inhibitors are largely synthetic peptide, peptidomimetic or fully non-peptide compounds [12][27]. Owing to increased stability, enhanced bioavailability, improved drug like property and easy accessibility by synthetic means, small molecule inhibitors are always preferred over proteins for therapeutic use [28]. Among the various inhibitor design strategies so far reported, the prodomain approach attracted most attention because of its effectiveness, versatility and sometimes enhanced selectivity [18], [26]. Besides this approach, incorporation of non-cleavable pseudo peptide bond [29] or unnatural amino acid [30] at P1-P1′ site of a potent peptide substrate based on prodomain or physiological protein sequence has also been used successfully to design inhibitors of PC enzymes. Based on somewhat similar idea, herein, we report for the first time, a new and innovative strategy for the design of a potent furin inhibitor. Our approach was primarily based on a specially constructed unnatural amino acid called “Eda or enediynyl amino acid” and its incorporation at the cleavage site of prodomain sequence of furin whose primary role is to regulate the protease activity by providing proper folding after binding. We show that incorporation of this highly reactive beta-turn inducing aromatic “Eda” moiety at the scissile P1-P1′ amide bond of a prodomain peptide of human furin led to a potent furin-inhibitor with inhibition constant Ki and IC50 in low nM ranges. For many years, enediynes and their derivatives were known to bind and cleave DNA especially of cancer cells through their oxidative actions. This occurred via in situ generation of bis-radicals by Bergman cyclo-aromatization reaction [31]. The ease of this cyclization depends on the nature and structure of enediynes [32][35]. Thus cyclic diynes of 8–10 member size as well as aza-enediynes have been shown to efficiently undergo Bergman cyclization under the induction of light, metal ions or elevated temperature due to their low activation barrier [reviewed in 32]. Due to this unique ability to cyclize and produce reactive bis-radicals, several enediyne derivatives have been designed as reactive species especially for DNA degradation [36][39]. So far several enediynes of both synthetic and fungal metabolite origins have been shown to display strong antitumor activity [31], [40]. Subsequently a few of these compounds have been approved as anti-cancer drugs. In a recent study Jones et al. examined the viability of proteins as targets of thermally and photo-activated enediyne derivatives and confirmed at the molecular level. They have shown that specifically designed enediyne derivatives can degrade proteins under suitable conditions [41][43]. Based on this observation, we hypothesize that such functional derivatives may also interact with catalytically active proteins such as protease like furin and thereby regulate its enzymatic and functional activity. For efficient binding with the target enzyme furin, we propose that such above moiety must carry a furin recognition peptide sequence. Thus we prepared a novel enediynyl peptide using a combination of organic and peptide chemistry and demonstrated its potent furin inhibitory activity both in vitro and cellular models. We first described the synthesis of Fmoc-protected “Eda” and then incorporated it into a furin substrate namely hfurin98–112 peptide at its furin cleavage site. The biochemical study showing anti-furin activity of this peptide analog towards a fluorogenic peptide substrate as well as physiological precursor proteins such as growth factors proPDGF-A, B and proVEGF-C are described in the present study.


Inhibition of Furin, PC5 and PC7 by Aromatic Enediyne Compounds

Most aromatic enediyne compounds are chemically highly reactive and can easily generate upon heating reactive bis-radical species via Bergman cyclo-aromatization reaction [31], [32]. It is a possibility that these reactive intermediates may then react with one or more of the catalytic amino acid residues His, Ser or Asp of PC-enzymes leading to chemical modifications of latter. This notion is supported by several studies involving interactions of amino acids either free or within protein sequences [41][46]. Based on this rationale we proposed that such types of molecules may therefore inhibit the protease activities of these enzymes. To test this hypothesis, we first synthesized several aromatic enediyne derivatives [44] and examined in vitro their effects on proteolytic activities of three key members of PC-family enzymes namely furin, PC5 and PC7. In vitro enzyme assay of PCs against Boc-RVRR-MCA substrate (50 µM), in the absence and presence of various synthetic aromatic enediyne compounds (Fig. 1) indicated weak to modest inhibitory activities of these compounds. Among the PCs examined, the most potent inhibitory activity was noted against PC7 for compound AB-2 which displayed an IC50 value of 8.5 µM. For furin, the highest inhibitory activity was also noted with AB-2 with IC50 value of 10.5 µM. Except for minor protease activating effect of AB-3 towards PC7, all other enediyne compounds exhibited inhibitory effects towards furin, PC5 and PC7 with IC50 values ranging from 8.5 to 160 µM depending on the nature of the enzyme and the enediyne compound used. This is the first report of PC-inhibitory activity of an enediyne compound. This finding prompted us to the idea of incorporating an enediyne function within a peptide sequence which may enhance the potency and selectivity of furin inhibition. To accomplish this, we designed and synthesized an enediynyl amino acid (Eda) derivative with its amino terminal protected by Fmoc (9H-fluoren-9-ylmethoxy carbonyl) group so that it can be directly used in solid phase peptide synthesis.

Figure 1. List of synthetic aromatic enediyne derivatives and their effects on protease activities of Proprotein Convertases Furin, PC5 and PC7.

The table shows the IC50 values for inhibition of recombinant proprotein convertases furin, PC5 and PC7 by various aromatic enediyne compounds. The enzyme assay was carried out by using the fluorogenic peptide substrate Boc-RVRR-MCA (50 µM final concentration) as described in [27]. ND  =  not determined.

Synthesis of Fmoc-Eda (I)

Synthesis of Fmoc-Eda (I) was accomplished by adopting he chemistry similar to that earlier reported by us [44], [47]. The multiple steps involved in the synthesis are shown schematically in self explanatory way in Fig. 2A. All synthetic details and procedure were described under Materials and Methods section.

Figure 2. Design of enediyne-based furin inhibitor.

Figure 2A. Scheme for chemical synthesis of Fmoc protected enediynyl amino acid (Eda). The reagents used for coupling or chemical reaction in various steps are shown at the footnotes of the scheme. Figure 2B. Design of β-turn mimetic furin inhibitor based on enediynyl amino acid (Eda) and profurin98–112. The figure (left panel) shows the structures of furin-Eda peptide (II) and its cyclized form (IIa) following Bergman cyclo-aromatization reaction. The right panel shows the mechanism and electron transfer of Bergman cyclization reaction with the formation of a bis radical intermediate. R  =  Any group; the dotted line indicates hydrogen bonding.

Peptide Selection for Incorporation of Eda

For incorporation of Eda unit, we selected the sequence (98–112) from human furin prodomain (shown within a box in Fig. 3). that comprises its autocatalytic primary cleavage site Arg-Lys-Thr-Arg-Arg107↓Asp-Val Various studies have shown that such a peptide bond is efficiently cleaved by furin (shown by vertical arrow) in both in vitro and ex vivo conditions [11], [18], [26]. In addition, this segment of furin pro-region has been found to be highly conserved across the species [26].

Figure 3. Complete amino acid sequence of human preprofurin.

Various domains are highlighted as indicated below: Underlined residues (129–427): Peptidase S8 (Subtilase) domain, (full catalytic domain of hfurin is considered as 108–438); Residues in italics (1–24): Signal peptide; Bold residues (25–107): Prosegment; Residues with underlined italics (484–575): P-domain; Residues with bold underlined (719–741): Transmembrane. The catalytic residues Asp153, His194, Ser368 are shown in bold larger fonts within circles. The peptide segment shown within the box was used for incorporation of “Eda” moiety.

Synthesis, Purification and Characterization of Furin-Eda-Peptide (II)

The above furin-Eda-peptide (II) contains a highly reactive β-turn inducing unnatural Eda-amino acid inserted between the scissile Arg-Asp amide bond. It is likely that such a peptide analog will be sensitive to changes in pH, metal ion concentrations and other environmental conditions such as UV light [32] that may lead to the formation of a cyclic derivative (IIa) (Fig. 2B) via Bergman cyclo-aromatization reaction. Such chemical transformation and modification may induce protease inhibitory activity to the peptide derivative. Peptide (II) was synthesized by HATU/DIEA (Diisopropyl ethyl amine) mediated solid phase Fmoc chemistry [18], [26] and purified by RP-HPLC (Fig. 4A, upper panel) using a C18 semipreparative column. The peak eluting at Rt  = 26.5 min was collected and analyzed by a second HPLC-run on an analytical C18 column when it exhibited a single peak at nearly identical retention time showing its high degree of purity (Fig. 4A, lower panel). The identity of the peptide was further confirmed by SELDI-tof mass spectrometry which displayed a peak at m/z  = 2111 in consistent with its calculated molecular weight (MW  = 2110) (Fig. 4B). The second peak observed at m/z  = 2128 may be due to the formation of an oxidized form of II, since it is ∼16 mass unit higher than the molecular ion. However other explanation may also exist.

Figure 4. Purification and characterization of furin-Eda peptide.

Figure 4A. RP-HPLC chromatograms of furin-Eda-peptide (II). Upper panel: HPLC for crude material obtained directly from solid phase synthesis (using C18-semi preparative column), lower panel: HPLC for purified material (using C18 analytical column). mAUFS  =  milli absorbance units full scale. Figure 4B. SELDI-tof mass spectrum of purified furin-Eda-peptide (II). It shows major peaks at m/z 2111 and 2118 for (M+H)+ and (M+H+oxygen)+ ions respectively.

Furin Inhibition by Eda Peptide (II)

Both progress curve and stopped-time assays with the fluorogenic substrate Boc (butyloxy)-RVRR-MCA (4-methyl coumarin 7-amide) (Figs. 5A and B) showed that Eda-peptide (II) inhibited furin activity in vitro with a high degree of potency. The progress curve assay (Fig. 5A), indicated that 125 nM of (II) was able to block furin activity almost completely against the above substrate (20 µM). As measured by the slope (s) of each curve shown within parenthesis in the graph, this effect was found to be concentration-dependent. The measured IC50 value was found to be ∼70 nM. Furthermore, Dixon plots based on stop-time assay at three different substrate concentrations 10, 20 and 40 µM, (Fig. 5B) indicated an inhibition constant (Ki) of 39.6 nM for furin inhibition by (II). The pattern of the graph also confirmed the competitive nature of inhibition suggesting the binding of Eda-peptide with the catalytic domain of furin. Using another substrate namely the intramolecularly quenched fluorogenic peptide (Abz-AEQDRNTR761↓EVFAQ-Tyx-A), where Abz  = 2-amino benzoic acid, Tyx  = 3-nitro tyrosine) derived human SARS corona virus spike protein [8], we noted that (II) blocked its processing with measured IC50 value being ∼193±12 nM (Fig. 5C).

Figure 5. Furin inhibition by furin-Eda peptide.

Figure 5A. Progress curves showing inhibition of furin activity by furin-Eda-peptide (II). The assay was conducted using Boc-RVRR-MCA (20 µM) as fluorogenic substrate. Figure 5B. Dixon plots showing inhibition of furin activity by furin-Eda-peptide (II). The inhibition was studied using three different concentrations (as indicated) of Boc-RVRR-MCA fluorogenic substrate (see Materials and Methods section for details). RFU  =  Raw fluorescence unit. Figure 5C. Inhibition of furin-mediated cleavage of hSARS-CoV fluorogenic peptide by furin-Eda-peptide (II). Furin-Eda-peptide blocks furin cleavage of intramolecularly quenched fluorogenic peptide hSARS-CoV spike754–766 Abz-AEQDRNTR761⇓ EVFAQ-Tyx-A (Abz  = 2-Amino benzoic acid, fluorescent group and Tyx  = 3-Nitro tyrosine, fluorescence quench group).

Effect of Furin-Eda-Peptide on proPDGF-A and proVEGF-C Processing

Fig. 6 (left lower panel) showed the western blot results using FLAG antibody on the effect of furin-Eda-peptide (50 µM) on furin processing of FLAG-labeled proPDGF-A in CHO cells. The result was compared in parallel with the commercial furin inhibitor Dec (decanoyl)-RVRR-cmk (chloromethyl ketone) [48] and the 83-mer synthetic full length prodomain protein of hfurin [49]. Like these two inhibitors, our Eda-peptide was also able to block efficiently the cleavage of 22 kDa pro-PDGF-A to 14 kDa mature PDGF-A (Fig. 6, upper panel). This was reflected by the strong appearance of 22 kDa proPDGF-A band which was completely absent in the control experiment done in parallel without the presence of any inhibitor. In addition Fig. 6 (lower panel, right) showed by western blot using VEGF-C antibody, the effect of furin-Eda-peptide (50 µM) on furin-mediated processing of proVEGF-C in CHO cells. The effect was compared in parallel with that done with the known furin inhibitor dec-RVRR-cmk. The figure illustrated that like dec-RVRR-cmk, 50 µM of furin-Eda peptide was able to block significantly the cleavage of 50 kDa proVEGF-C to 28 kDa mature VEGF-C, confirming its furin inhibitory activity under ex vivo condition.

Figure 6. Schematic diagrams showing processing of hproPDGF-A and hproVEGF-C labeled at the C-terminus with a FLAG leading to their mature forms.

The two upper panel figures highlight the furin processing sites (shown by vertical arrow) of the two precursor proteins. The lower panels show the effects of various furin inhibitors including the furin-Eda peptide (II) on the processing of proPDGF-A (left) and proVEGF-C (right) in CHO cell lines using western blot analysis. Pep-cmk  =  Dec-RVRR-cmk (chloromethyl ketone), Furin-pro  =  Synthetically made 83-mer full length hfurin prodomain (hfurin25–107) [49]. Actin levels were measured by western blots and used as controls for quantitation purpose.

Effect of Furin-Eda-Peptide on proPDGF-B Processing

Furin-Eda-peptide (II) was also able to block furin-mediated processing of 31 kDa pro-PDGF-B to 17 kDa mature form in CHO cells in a concentration-dependent manner (Fig. 7). The results were highly comparable with those conducted in parallel with α1-Pdx protein, another known potent inhibitor of furin [50]. It is interesting to note that neither inhibitors displayed any effect on the formation of 22 kDa intermediate form of PDGF-B - whose exact identity as well as biological and functional role has not yet been fully explored.

Figure 7. Schematic diagram showing proteolytic processing of hproPDGF-B leading to its mature form.

Upper panel highlights the two processing sites including one by furin that lead to the production of its functionally active mature form; Lower panel: The lower panel shows the effects of Eda peptide (II) (left) and α1-Pdx (right), a known furin inhibitor on the processing of proPDGF-B in CHO cells at various concentration levels (5–15 µM) as indicated. Actin levels were measured by western blots and used as controls for quantitation purpose.

Interaction between Eda-Peptide and Recombinant Furin

In order to understand the plausible mechanism of furin inhibition by furin-Eda-peptide (II), recombinant furin protein was incubated with the Eda-peptide at various concentrations at 37°C for 24 h and the mixture was analyzed for protein bands by silver staining and western blots using anti-furin antibody. The results were compared with those of recombinant furin samples fresh as well as incubated in the absence of Eda-peptide. Western blot data (Fig. 8, left lower panel) indicated that Eda-peptide protected furin from self-degradation as the 55 kDa soluble furin band gradually became more intense as the concentration of Eda-peptide was increased. The results were also depicted by densitometric analysis of the observed bands (Fig. 8, left upper panel). A similar conclusion was also reached by protein staining data of the bands with silver ions (Fig. 8, right panel), which exhibited more intense 55 kDa furin band in the presence of higher concentration of Eda-peptide.

Figure 8. Western blots and SDS-gel electrophoresis with silver staining of fresh recombinant furin sample and samples after 24 h incubation in the absence and presence of various concentrations of furin-Eda-peptide (II).

Left panel: Immunoblot analysis of various furin samples using furin-specific antibody. Right panel: Silver stains of same samples in SDS-gel electrophoresis for visualization of all protein bands. The 55 kDa band shown within a box represents the soluble form of recombinant furin protein. FF  =  Fresh furin sample; std  =  Standard.sample, Ab  =  Antifurin antibody.

3D Model Structure of Furin-Eda Peptide

Energy minimized 3D model structures of furin-Eda-peptide before and after Bergman cyclo-aromatization reaction were computed using hyperchem program and the structures were depicted in Fig. 9. It showed that the cyclic form of furin-Eda-peptide (IIa) exhibited a significant change in the backbone conformational geometry particularly at the C-terminal end of the molecule compared to the corresponding acyclic form (II).

Figure 9. 3D model structures of acyclic (II) and cyclic (IIa) furin-Eda-peptide based on hyperchem.

The structures were generated by energy minimization using hyperchem program (version 7.5). The peptide backbones were shown in thick yellow lines.

Docking of Furin-Eda-Peptide with the P-Domain of Furin Enzyme

Enediynes are known to undergo Bergman cyco-aromatization reaction even under mild condition (32). We therefore postulate that the observed inhibition of furin activity by furin-Eda-peptide may be mediated by the cyclic (IIa) rather than the acyclic (II) form. Our postulate is based on the speculation that the potency of binding will be increased upon cyclo-aromatization reaction due to increased π-stacking interaction. Further work using proton NMR spectroscopy would be necessary to provide more convincing evidence for the above hypothesis [51]. However owing to above proposition, docking studies were performed between various domains of furin particularly its P-domain and the cyclized furin-Eda-peptide (IIa) using autodock program. The results were shown in Figs. 10A and 10B (expanded) which revealed an efficient docking and potent interaction with the C-terminal segment of furin within the residues 487AQAR----------ANNY560. A more detail investigation revealed strong H-bond interactions among several residues within the domain (Val548---------Glu-Ala557) and the cyclized furin-Eda peptide (Fig. 10B, enlarged portion). In fact our docking results identified a small segment 548VLEIENTSEA557 that interacts best with the cyclized Eda peptide (IIa). No significant interactions were noticed with the acyclic furin-Eda-peptide (II) suggesting the possibility that (IIa) might be the species responsible for interaction with furin as indicated above and this may ultimately lead to inhibition of furin activity which is composed of crucial catalytic residues D153, H194, and S368 as well as the oxyanion N295.

Figure 10. Interaction of furin-Eda peptide (II/IIa) with furin enzyme.

Figure 10A. Docking of cyclized furin-Eda peptide (IIa) with furin P-domain (residue 487–560). Cyclized furin-Eda-peptide (IIa) is shown in space filled structure in red while the furin P-domain (residue 487Ala-Gln-Ala-Arg---------Ala-Asn-Asn-Tyr560) is depicted in stick mode and CPK (Corey, Pauling, Koltun) colors. This is the best fit docking structure obtained between the cyclic furin-Eda peptide (IIa) and any part of furin protein. Figure 10B. An expanded area of docking of furin P-domain with cyclized furin-Eda peptide (IIa) (shown in red). An enlarged segment of P-domain of furin characterized by the sequence 548VLEIENTSEA557 showing its strong interaction with cyclized furin-Eda-peptide (IIa) (shown in red). Several observed strong H-bondings between the two segments were shown by dotted lines.

Circular Dichroism (CD) Spectra of Eda-Peptide

Circular dichroism (CD) spectrum [52] was conducted to evaluate the secondary structure of furin-Eda peptide which might play a role in its furin-inhibitory activity. The CD spectra of furin-Eda peptide in water at various pH conditions were depicted in Fig. 11A. The spectra showed that the peptide exists mostly in beta-sheet and random structures with very little helix content (<10%) under all pH conditions (5.5–8.0) tested. There were slight changes in CD profile particularly at 200–205 nm area following changes in pH condition. This may possibly due to partial transformation of sheet structure to random or turn structure. Addition of fluorinated alcohol such as TFE (a helix promoting solvent) led to the formation of significant helical structure at the expense of its sheet structure (Fig. 11B). This observation suggested that TFE can promote helix structure in furin-Eda-peptide which might alter its furin inhibitory property.

Figure 11. Circular dichroism and fluorescence spectra of furin-Eda peptide (II).

Figure 11A. Overlay of Circular Dichroism (CD) spectra of furin-Eda-peptide (II) (0.5 mg/ml) in water at various pHs as shown. An expanded portion of the spectra showing the effects of pH on the position of the peak minima was shown directly beneath the full spectra. Figure 11B. Overlay of CD spectra of furin-Eda-peptide (II) (0.5 mg/ml) in various solvent systems as indicated. The gradual conversion of the spectra to more helix rich structure characterized by the presence of a maximum at ∼195 nm followed by two broad minima at ∼205 and ∼222 nm are noticeable. Figure 11C. Emission spectra (λex = 320 nm) of Eda-peptide (II) in tetrafluoro ethanol (TFE) at various CaCl2 concentrations. The spectra were recorded in TFE solvent (100 µl, peptide concentration  = 0.1 mM)) in the absence. Addition of CaCl2 to the medium quenches the fluorescence intensity in a dose dependent manner. 1 mM CaCl2 can fully suppress the fluorescence as shown by the spectrum.

Fluorescence Photophysical Property of Eda-Peptide

Since Eda-peptide contains aromatic and conjugated double and triple bonds in its structure we decided to examine its fluorescence spectroscopic property. In fact it was found to exhibit excitation and emission peaks at 320 and 440 nm respectively (data not shown). The emission spectra of furin-Eda-peptide in TFE in the absence and presence of various concentrations of CaCl2 which is required for furin activity were shown in Fig. 11C. The graph showed that upon addition of CaCl2 the peak at 440 nm observed in the emission spectrum gradually diminished depending on the amount of added CaCl2. In fact the peak was completely suppressed upon addition of equimolar quantity of CaCl2, suggesting a strong interaction between furin-Eda-peptide and CaCl2. A similar conclusion was also reached from CD spectra studies (not shown).


This study revealed for the first time that fully nonpeptide aromatic and heterocyclic enediyne compounds can inhibit furin activity in vitro with IC50 in low to medium micromolar ranges depending on the nature of the structure and type of substituent present. Enzyme inhibitory activity was also noticed towards other PC enzymes namely PC5 and PC7 (Fig. 1). Among the compounds tested, a 12-membered 1, 4-diaza enediyne heterocyclic ring compound with bis-benzyl substituent (AB-2) has been found to exhibit highest inhibitory activities against both furin and PC7 with IC50 of 8.5 and 10.5 µM respectively. However it was found to be a less potent inhibitor towards PC5, with IC50 of 34 µM. Thus clearly there was a lack of selectivity for inhibition when compared among these PCs. The next best furin inhibition was achieved with the compound AB-3 followed by AB-1. Interestingly while both AB-3 and AB-4 contain a common 13-membered 1–3 diaza ring structure, AB-1 is an acyclic molecule. The tetra aza compounds AB-6 and its Nickel-complex were found to be much poor inhibitors of furin.

In addition to above, our study for the first time showed that an enedynyl peptide can inhibit the protease activity of a PC enzyme such as furin. However while this manuscript is under review, the inhibition of chymotrypsin by an enediynyl peptide was reported in the literature [53]. Thus here we revealed that incorporating an enediynyl “Eda” function - a highly reactive and beta turn inducing amino acid [44] at the junction of P1-P1′ residues of a furin substrate derived from its prodomain primary catalytic site, led to a highly potent furin inhibitor. Other properly designed unnatural amino acids may also be incorporated instead of “Eda” to design other furin inhibitors. In the present design as our first choice, the prodomain sequence comprising (98–110) amino acid residues of human preprofurin was selected as the substrate. The significance of prodomain as well as its removal and or degradation during furin activation have been well documented in the past [2], [3], [5] and more recently in [54]. The presented data based on progress curve, Dixon plot and sigmoidal graph (Fig. 5) all indicated that furin-Eda-peptide (II) is a strong inhibitor of Proprotein Convertase furin. Furthermore the data confirmed the competitive nature of inhibition which was also supported by CD and fluorescence studies. The data also suggested that the furin inhibition by Eda-peptide is independent of the nature of the substrate used – be it a small peptide or a physiological protein. In fact (II) inhibited furin cleavages of hSARS coV peptide [55] as well as physiological protein substrates such as growth factor precursers. Although in the present study “Eda” was introduced between P1/P1′ amino acids, it will be more logical to replace or substitute P1′ residue by “Eda” which is expected to lead to even more potent and/or selective inhibitor of furin. Besides, other peptides substrates of furin derived from the processing site of its physiological proproteins can be employed to validate this new hypothesis of ours for protease inhibitor design. These aspects are currently being investigated in the laboratory.

Our studies involving cell lines expressing furin and its physiological substrates proPDGF-A, proVEGF-C and proPDGF-B indicated that Eda-peptide when added exogenously into the culture media during cell growth can efficiently block furin-mediated processing of above substrates leading to their bio-active mature forms in a concentration dependent manner. In most cases the effects with our furin-Eda peptide were comparable to those observed with the known furin inhibitors α1-Pdx [50] and Dec-RVRR-cmk [48]. In other cases the effects were slightly less pronounced but still significant. Thus for example western blot results showed that 50 µM of Eda-peptide blocked furin-mediated processing of proVEGF-C to mature VEGF-C to a similar extent compared to that obtained with 10 µM Dec-RVRR-cmk (Fig. 6). Similar observation was also noted for proPDGF-A processing. However, the Eda peptide was found to be more effective in blocking the cleavage of proPDGF-B. In fact, both Eda-peptide and α1-Pdx suppressed the cleavage of proPDGF-B to its mature form almost with identical efficiency (Fig. 7). Thus both in vitro and ex vivo studies involving small peptide as well as natural protein substrates confirmed the potent anti-furin activity of Eda-peptide (II). The observed Ki and IC50 values for Eda-peptide as measured against Boc-RVRR-MCA were found to be higher than that observed with bioengineered protein α1-Pdx [50] but were still in low nM range. Our studies confirmed that Eda-peptide can block furin cleavage of fluorogenic peptides as well as physiologically relevant proteins proPDGF-A, B and proVEGF-C. Proteolytic activation of these growth factor precursor proteins has been linked to tumor growth and progression as shown by the high level of expression of their mature forms in cancer cells compared to normal ones [7], [56][58]. Thus above research findings suggested that our Eda-peptide may play an important role in tumor suppression and intervention via the blockade of maturation by furin of precursor growth factor proteins. More potent and selective furin inhibitors based on “Eda” may be developed by choosing more efficient furin recognition sequences based on its known substrates.

Secondary structure analysis by circular dichroism spectra indicated that the Eda-peptide exhibited predominantly sheet and random structures with little content of helical structure in aqueous medium under physiological pH condition (pH 7.4). Change in pH has little effect on the secondary structure, although the spectrum profile at the minima showed significant differences. Moreover, addition of helix promoting solvent such as TFE led to a noteworthy increase in helix structure thereby suggesting that Eda-peptide is capable of adopting helix conformation depending on the nature and pH of the solvent. This structural behaviour is partly consistent with that found in the similar region of furin protein as revealed by its x-ray crystal structure [59], [60].

Molecular docking studies indicated that upon Bergman cyclization furin-Eda-peptide provided a more potent interaction and better contact with the P-domain of furin protein characterized by the segment 548Val-Leu-Glu-Ile-Glu-Asn-Thr-Ser-Glu-Ala557 which is located not too distant from the catalytic domain [61]. The complete catalytic domain of furin (108–438) is defined as the sequence segment beginning at the mature N-terminus and ending at the residue equivalent to the C-terminus of thermitase [61]. The above binding may lead to a significant change in conformation and folding pattern of furin catalytic structure leading to its loss of protease activity. No other docking could be noticeable between the Eda-peptide (cyclic or acyclic form) and any domain of furin. Thus, it is more likely that Eda-peptide upon Bergman cyclization may be a more effective inhibitor of furin although such conclusion would require further studies with the two purified forms of furin-Eda peptide and NMR Spectra. Moreover, in order to further expand the present study and examine the efficacy of Eda-peptide approach as a general method for inhibitor design for any protease including furin, other peptide sequences need to be examined. Moreover further studies in future using additional cell lines and animal models will shed more light on the mechanism of furin inhibition by Eda-peptide.

Materials and Methods


All Fmoc-protected amino acid derivatives (L-configuration), coupling reagents, resins for peptide synthesis as well as the fluorogenic substrate Boc-RVRR-MCA and furin inhibitor Dec-RVRR-cmk were purchased from Bachem Inc (King of Prussia, Pa, USA), Calbiochem Novabiochem Inc (San Diego, Ca, USA), Neosystems Inc, (San Diego, Ca, USA) or PE Applied Biosystems (Foster City, Ca, USA). The primary and secondary antibodies for PDGF-B, Actin and FLAG tag were bought from Santa Cruz Biotechnology Inc (Santa Cruz, Ca, USA) whereas all reagents for immuno-blotting and SDS-PAGE were purchased from Biorad Labs (Hercules, Ca, USA). Surface Enhanced Laser Desorption Ionization and Matrix Assisted Laser Desorption time of flight mass spectra were recorded using Ciphergen Protein Chips (San Diego, Ca, USA) and Voyageur DE Pro (PE-Applied Biosystems, Framingham, Ma, USA) respectively. The energy absorbing matrices α-cyano 4-hydroxy cinnamic acid and 1, 2-dihydroxy benzoic acid and silica gel 60 for column chromatography were purchased from Sigma Chemical Company (Mississauga, On, Canada) and Sigma-Aldrich Chemical Company (St Louis, Mo, USA) respectively. The solvents used were HPLC grade and were purchased from Fisher Chemical Company, Mississauga, On, Canada. RP-HPLC was performed on C18 column (analytical and semi-preparative) using Varian instrument and Star software program. The gradient used was as described in [27].

Synthesis of Aryl Enediyne Compounds AB1-6

Chemical syntheses and full characterizations of various aryl enediyne compounds AB1, 2, 3, 4, 5, 6 and 6-Ni listed in Fig. 1 were accomplished previously using multiple chemical steps as described in [32].

Synthesis of Fmoc-Enediynyl Amino Acid (Eda) (I)

Fmoc enediynyl amino acid (Eda) was synthesized using several steps as described in (42). In brief, the synthesis was accomplished first by Pd (0)-mediated Sonogashira coupling of 1, 2-dibromo benzene with 4-pentynoic acid benzhydryl ester in presence of cuprous bromide in dry triethylamine under refluxing condition for 4 h in an inert atmosphere. After aqueous work up, the crude oily residue was purified by column chromatography using silica gel 60 (eluted with petroleum ether: Ethyl acetate  = 30∶1) to afford the eneyne ester [5-(2-Bromo-phenyl)-pent-4-ynoic acid benzhydryl ester]. A second round of Sonogashira coupling of eneyne ester with 3-butyne-1-ol and subsequent purification yielded the enediyne hydroxyl ester [5-[2-(4-Hydroxy-but-1-ynyl)-phenyl]-pent-4-ynoicacid benzhydryl ester]. Thus enediyne hydroxyl ester obtained was converted to methyl toluene sulphonate or mesylate and was subsequently reacted with sodium azide in dry DMF to furnish the corresponding enediyne azido ester [5-[2-(4-Azido-but-1-ynyl)-phenyl]-pent-4-ynoic acid benzhydryl ester]. The azido functionality was then reduced to amine on treatment with triphenyl phosphine and H2O in THF. The amine [5-[2-(4-Amino-but-1-ynyl)-phenyl]-pent-4-ynoic acid benzhydryl ester] was protected with Fmoc by reaction with Fmoc-chloride under basic condition in methanol to afford Fmoc-NH-Eda-benzhydryl ester which was then subjected to deprotection by TFA/anisole in dry dichloromethane to furnish the desired Fmoc-Eda (I), [5-[2-(4-Fmoc-amido-but-1-ynyl)-phenyl]-pent-4-ynoic acid] whose calculated molecular weight (449) was found to be in good agreement with the observed molecular weight (450).

Synthesis of Furin-Eda Peptide (II)

Peptide synthesis was accomplished by Fmoc-based solid phase chemistry (0.25 mmol scale) using Fmoc-PAL-PEG-PS (polyamino linker polyethylene glycol) resin, substitution  = 0.55 meq/gm resin). [PAL  =  [{5-(4-amino methyl 3.5-dimethoxy phenoxy) valeric acid, PEG  =  polyethylene glycol and PS  =  polystyrene resin)] and HATU (O-hexafluoro-phospho-[7-azabenzotriazol-1-yl]-N, N, N', N'-tetramethyluronium)/DIEA {di-isopropylethylamine} coupling agent (30). Following side chain protecting groups were used for various Fmoc protected amino acids: t-butyloxy carbonyl (tBoc) for Lys; tertiary butyl (tBut) for Thr, Tyr, Asp, Glu, (2, 2, 4, 6, 7-pentamethyl dihydrobenzofuran-5-sulfonyl) (Pbf) for Arg and finally trityl (Trt) for Gln. Following completion of synthesis, the crude peptide was cleaved from the resin and fully deprotected with Reagent B [26], [27].

Purification and Characterization of Peptide (II)

The crude peptide (II) as obtained above was purified by RP-HPLC using semi-preparative and analytical C18 columns in combination. Peaks were collected and examined by mass spectrometry. The peak eluting at retention time (Rt)  = 26.5 min was characterized as furin-Eda peptide (II) by both SELDI and MALDI-tof mass spectrometry using CHCA matrix [MW calculated  = 2110, observed 2111 (M++H), 2128 (M++H+O.) and 2133 (M++H+Na)].

Source of Enzymes

While pure soluble recombinant h (human) furin was obtained commercially from New England Biolabs (Boston, Ma, USA), recombinant m (mouse) PC5 and soluble hPC7 were obtained in partially purified form as described earlier [18].

Determination of Kinetic Parameters, Ki and IC50 for Inhibition of Furin by Eda Peptide (II)

Inhibition constant Ki for inactivation of furin by Eda peptide (II) was determined by Dixon plot using three different concentrations of substrate Boc-RVRR-MCA and various concentrations of the inhibitor ranging from 0–300 nM. For IC50 determination, a sigmoidal graph was generated by plotting the reaction rate as measured by raw fluorescence unit (RFU) released per hour against the logarithm of concentration of inhibitor. In case of latter, the substrate used was an intramolecularly quenched fluorogenic peptide, Abz-AEQDRNTR761↓EVFAQ-Tyx-A (Abz  = 2-Amino benzoic acid, Tyx  = 3-Nitro tyrosine) derived from residues {754–766} of hSARS corona virus spike glycoprotein as previously reported [8].

Effect of Furin-Eda Peptide on the Processing of proPDGF-A in CHO Cells

CHO-cells expressing FLAG-tagged PDGF-A were grown in DMEM medium as described (43) until the cells achieved ∼80% confluency (24 h), At this stage the medium was removed, cells were washed and grown in fresh buffer supplemented with furin-Eda peptide (50 µM final concentration). The media and cells were harvested after another 24 h cell growth. The collected media were concentrated ∼20-fold using centricon filtration system (Amersham Biosciences Inc, cut off MW  = 3 kDa) and subjected to western blot analysis using FLAG antibody for the presence of full length proPDGF-A and its C-terminal mature form obtained following cleavage by endogenous furin present in CHO cells. In parallel, identical experiments were performed by growing cells in the absence or presence of known furin inhibitors namely dec-RVRR-cmk (10 and 50 µM concentrations) and synthetic 83-mer full length furin-prodomain protein (50 µM final concentration), previously described by us [49]. For quantitative purpose, each sample was also analyzed for the presence of actin by immunoblot using a specific antibody.

Effect of Furin-Eda Peptide on the Processing of proVEGF-C in CHO Cells

CHO-cells expressing FLAG-labeled proVEGF-C [57] were grown in DMEM medium as described above in the absence and presence of furin-Eda peptide and the furin inhibitor Dec-RVRR-cmk (each 50 µM concentration). The presence of VEGF-C precursor and its C-terminal processed form generated by furin cleavage were assessed by western blot analysis using FLAG antibody while the level of actin (control house keeping protein) was analyzed by immunoblot for quantitation purpose.

Effect of Furin-Eda Peptide on the Processing of proPDGF-B in CHO Cells

CHO-cells expressing endogenous proPDGF-B [58] were grown as described above in the absence and presence of various concentrations ranging from 0.5 to 15 µM of either furin-Eda peptide or α1-Pdx, a known furin inhibitor [50]. Western blots were performed for the presence of proPDGF-B and its processed form using PDGF-B specific antibody. In parallel samples were also analyzed for actin levels.

Effect of Furin-Eda Peptide on Recombinant Furin Protein

Recombinant C-terminal truncated soluble furin [2 µl, activity  = 4U (unit), MW 55 kDa, 1 U of activity releases 1 pmol of free AMC from 100 µM fluorogenic Boc-RVRR-MCA substrate in one minute at 37°C] was incubated for 24 h at 37°C in 20 mM Tris +25 mM Mes +2.5 mM CaCl2, pH 7.4 in the absence or presence of furin-Eda-peptide (II) at various concentrations ranging from 0–30 µM. Samples were analyzed by western blot (using furin antibody from SantaCruz) as well as silver staining for the presence of all protein bands.

Circular Dichroism (CD) Spectra of Furin-Eda (II) Peptide

All CD spectra (run in triplicates and then averaged) were recorded at 25°C in Jasco-810 spectropolarimeter (Easton, Md, USA) in 0.1 cm thick rectangular quartz cell in a total volume of 300 µl (100 µM final concentrations) at 0.1 nm intervals from 185–240 nm wave length. The final corrected CD spectra were obtained by subtracting the spectrum of the control solvent run in parallel from that of the sample spectrum and analyzed using CD. Estima and Contin software programs for α-helix, β-pleated sheet, β-turn, and random structures were used (Softspec Company, NJ, USA) [52].

Fluorescence Spectrum of Furin-Eda Peptide (II)

The fluorescence emission spectrum of furin-Eda peptide (0.1 mM) was recorded at a fixed excitation wave length 320 nm in a well plate in tetrafluoro ethanol (TFE) solvent (100 µl) at ambient temperature in absence or presence of added (2 or 10 µl) CaCl2 solution.(1 mM stock solution).

Molecular Model of Furin-Eda-Peptide Before and After Bergman Cyclo-Aromatization

Theoretical 3D molecular model structures were generated for Eda-peptide both acyclic (II) and cyclic (IIa) forms by using Hyperchem software (version 7.5, Hypercube Inc) based on the energy minimization using Polak-Ribiere algorithm program.

Docking of Furin-Eda-Peptide with Furin

Docking of Eda-peptide, both acyclic and cyclic forms with the catalytic domain of hfurin (sequence accession number  =  NP_002560) based on its known crystal structure (pdb file 1p8j) [59], [60] was accomplished by using autodock and modeler programs (for comparative protein structure modeling by satisfaction of spatial restraints) (


We thank Y. Feng and A. Chen for technical assistance with cell and peptide synthesis works.

Author Contributions

Conceived and designed the experiments: AB. Performed the experiments: AB DM SB MK SSB. Analyzed the data: AB AMK. Contributed reagents/materials/analysis tools: AB. Wrote the paper: AB. Took part in discussion and formatting: SB.


  1. 1. Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, et al. (2008) The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 40: 1111–1125.
  2. 2. Thomas G (2002) Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nature reviews, Molecular Cell Biology 3: 753–766.
  3. 3. Rholam M, Fahy C (2009) Processing of peptide and hormone precursors at the dibasic cleavage sites. Cell Mol Life Sci 66(13): 2075–2091.
  4. 4. Chrétien M, Seidah NG, Basak A, Mbikay M (2008) Proprotein convertases as therapeutic targets. Expert Opin Ther Targets 12(10): 1289–1300.
  5. 5. Seidah NG, Prat A (2002) Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 38: 79–94.
  6. 6. Kido H, Okumura Y, Takahashi E, Pan HY, Wang S, et al. (2008) Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. J Mol Genet Med 3(1): 167–175.
  7. 7. Khatib AM, Siegfried G, Chrétien M, Metrakos P, Seidah NG (2002) Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160(6): 1921–1935.
  8. 8. Bergeron E, Vincent MJ, Wickham L, Hamelin J, Basak A, et al. (2005) Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus. Biochem Biophys Res Commun 326(3): 554–63.
  9. 9. Basak A, Zhong M, Munzer , JS , Chrétien , M , Seidah , NG (2001) Implication of the proprotein convertases Furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola and Respiratory Syncytial viruses – a comparative analysis using fluorogenic peptides. Biochem J 353: 537–545.
  10. 10. Basak A (2005) Inhibitors of proprotein convertases. J Mol Med 83: 844–855.
  11. 11. Fugère M, Day R (2005) Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 26: 294–301.
  12. 12. Jiao GS, Cregar L, Wang J, Millis SZ, Tang C, et al. (2006) Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA 103(52): 19707–19712.
  13. 13. Coppola JM, Bhojani MS, Ross BD, Rehemtulla A (2008) A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10(4): 363–370.
  14. 14. Shiryaev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, et al. (2007) Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 282(29): 20847–20853.
  15. 15. Fugere M, Appel J, Houghten RA, Lindberg I, Day R (2007) Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol Pharmacol 71(1): 323–332.
  16. 16. Rabah N, Gauthier D, Wilkes BC, Gauthier DJ, Lazure C (2006) Single amino acid substitution in the PC1/3 propeptide can induce significant modifications of its inhibitory profile toward its cognate enzyme. J Biol Chem 281: 7556–7567.
  17. 17. Bhattacharjya S, Xu P, Wang P, Osborne MJ, Ni F (2007) Conformational analyses of a partially-folded bioactive prodomain of human furin. Biopolymers 86: 329–344.
  18. 18. Zhong M, Munzer JS, Basak A, Benjannet S, Mowla SJ, et al. (1999) The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J Biol Chem 274: 33913–33920.
  19. 19. Kowalska D, Liu J, Appel JR, Ozawa A, Nefzi A, et al. (2009) Synthetic small-molecule prohormone convertase 2 inhibitors. Mol Pharmacol 75(3): 617–625.
  20. 20. Wang S, Han J, Wang Y, Lu W, Chi C (2008) Design of peptide inhibitors for furin based on the C-terminal fragment of histone H1.2. Acta Biochim Biophys Sin (Shanghai) 40(10): 848–854.
  21. 21. Coppola JM, Hamilton CA, Bhojani MS, Larsen MJ, Ross BD, Rehemtulla A (2007) Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem 364(1): 19–29.
  22. 22. Jiao GS, Cregar L, Wang J, Millis SZ, Tang C, et al. (2006) Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA 103(52): 19707–19712.
  23. 23. Fugere M, Appel J, Houghten RA, Lindberg I, Day R (2007) Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol Pharmacol 71(1): 323–332.
  24. 24. Han J, Zhang L, Shao X, Shi J, Chi C (2006) The potent inhibitory activity of histone H1.2 C-terminal fragments on furin. FEBS J 273(19): 4459–4469.
  25. 25. Komiyama T (2005) Interaction of Eglin C variants with the extended subsites of the precursor processing proteases. Protein Pept Lett 12(5): 415–420.
  26. 26. Basak A, Lazure C (2003) Synthetic peptides derived from the prosegments of proprotein convertase 1/3 and furin are potent inhibitors of both enzymes. Biochem J 373: 231–239.
  27. 27. Basak A, Lotfipour F (2005) Modulating furin activity with designed mini-PDX peptides: Synthesis and in vitro kinetic evaluation. FEBS Let 579: 4813–4821.
  28. 28. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein–protein interactions: progressing towards the dream. Nat Rev Drug Disc 3: 301–317.
  29. 29. Nielsen PE (2004) Pseudopeptides in drug discovery, Wiley-VCH, Verlag GmbH & Co.
  30. 30. Basak A, Schmidt C, Ismail AA, Seidah NG, Chrétien M, et al. (1995) Peptidyl substrates containing unnatural amino acid at the P'1 position are potent inhibitors of prohormone convertases. Int J Pept Protein Res 46(3–4): 228–237.
  31. 31. Jones , RR , Bergman , RG (1972) p-Benzyne: Generation as an intermediate in a thermal isomerization reaction and trapping evidence for the 1, 4-benzenediyl structure. J Am Chem Soc 94: 660–661.
  32. 32. Basak A, Mandal S, Bag SS (2003) Chelation-controlled Bergman cyclization: Synthesis and Reactivity of Enediynyl ligands. Chem Rev 103: 4077–4094.
  33. 33. Basak A (2008) Enediynes and related structures in medicinal and bio-organic chemistry. Curr Top Med Chem 8(6): 435.
  34. 34. Choy N, Blanco B, Wen J, Krishan A, Russel KC (2000) Photochemical and Thermal Bergman Cyclization of a Pyrimidine Enediynol and Enediynone, Org Lett 2: 3761–3764.
  35. 35. Greddiak M, Jeri I (2007) Enediyne compounds – new promises in anticancer therapy. Acta Pharm 57: 133–150.
  36. 36. Basak A, Mandal S, Das AK, Bertolasi V (2002) Benzene fused monocyclic enediynyl amides: synthesis, reactivity and DNA-cleavage activity in comparison to the corresponding sulfonamides. Bioorg Med Chem Lett 12(6): 873–877.
  37. 37. Basak A, Shain JC (1998) Synthesis and thermal behaviour of a novel diazaenediyne and its copper(II)-complex. Tet Lett 39: 1623–1624.
  38. 38. Basak A, Kar M, Mandal S (2005) Dependence of reactivity of a novel 2,6-diamino pyridine-based enediyne on the extent of salt formation with external acids: a possible implication in pH based drug design. Bioorg Med Chem Lett 15(8): 2061–2064.
  39. 39. Basak A, Shain JC, Khamrai UK, Rudra KR, Basak A (2000) Nitrogen substituted cyclic enediynes: synthesis, thermal reactivity and complexation with metal ions. J Chem Soc, Perkin Trans1 12: 1955–1964.
  40. 40. Borders DB, Doyle TW, editors. (1995) Enediyne antibiotics as antitumor agents. NY city, NY, USA: Marcel Dekker Inc.
  41. 41. Fouad FS, Wright JM, Plourde G 2nd, Purohit AD, Wyatt JK, et al. (2005) Synthesis and protein degradation capacity of photoactivated enediynes. J Org Chem 70(24): 9789–9797.
  42. 42. Jones GB, Plourde GW 2nd, Wright JM (2000) Understanding enediyne-protein interactions: diyl atom transfer results in generation of aminoacyl radicals. Org Lett 2(6): 811–813.
  43. 43. Jones GB, Wright JM, Hynd G, Wyatt JK, Yancisin M, et al. (2000) Protein-degrading enediynes: library screening of Bergman cycloaromatization products. Org Lett 2(13): 1863–1866.
  44. 44. Basak A, Bag SS, Basak A (2005) Design and synthesis of a novel enediynyl pentapeptide with predominantly beta-turn structural motif and its potential as a fluorescence-based chemosensor. Bioorg Med Chem 13(12): 4096–4102.
  45. 45. Zein N, Casazza AM, Doyle TW, Leet JE, Schroeder DR, et al. (1993) Selective proteolytic activity of the antitumor agent kedarcidin. Proc Natl Acad Sci USA 90(17): 8009–8012.
  46. 46. Zein N, Solomon W, Colson KL, Schroeder DR (1995) Maduropeptin: an antitumor chromoprotein with selective protease activity and DNA cleaving properties. Biochemistry 34(36): 11591–11597.
  47. 47. Basak A, Rudra KR, Bag SS, Basak A (2002) Synthesis, reactivity and conformational preferences of novel enediynyl peptides: a possible scaffold for β-sheet capping turns. J Chem Soc Perkin Trans 1 15: 1805–1809.
  48. 48. Angliker H (1995) Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J Med Chem 38(20): 4014–4018.
  49. 49. Basak A, Chen A, Scamuffa N, Mohottalage D, Basak S, et al. (2009) Blockade of furin activity and furin-induced tumor cells malignant phenotypes by the chemically synthesized human Furin prodomain. Biochim Biophys Res Commun, under revision.
  50. 50. Jean F, Thomas L, Molloy SS, Liu G, Jarvis MA, et al. (2000) A protein-based therapeutic for human cytomegalovirus infection. Proc Natl Acad Sci USA 97(6): 2864–2869.
  51. 51. Bhattacharjya S, Xu P, Xiang H, Chrétien M, Seidah NG, Ni F (2001) pH-induced conformational transitions of a molten-globule-like state of the inhibitory prodomain of furin: implications for zymogen activation. Protein Sci 10(5): 934–942.
  52. 52. Whitmore L, Wallace BA (2008) Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 89(5): 392–400.
  53. 53. Dutta S, Basak A, Dasgupta S (2009) Design and synthesis of enediyne-peptide conjugates and their inhibiting activity against chymotrypsin. Bioorg Med Chem 17(11): 3900–3908.
  54. 54. Gawlik K, Shiryaev SA, Zhu W, Motamedchaboki K, Desjardins R, et al. (2009) Autocatalytic Activation of the Furin Zymogen Requires Removal of the Emerging Enzyme's N-Terminus from the Active Site. PLoS ONE 4(4): e5031 (1–12.
  55. 55. Basak A, Mitra A, Basak S, Pasko C, Chrétien M, et al. (2007) A fluorogenic peptide containing the processing site of human SARS corona virus S-protein: kinetic evaluation and NMR structure elucidation. Chembiochem 8(9): 1029–1037.
  56. 56. Siegfried G, Khatib AM, Benjannet S, Chrétien M, Seidah NG (2003) The proteolytic processing of pro-platelet-derived growth factor-A at RRKR(86) by members of the proprotein convertase family is functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. Cancer Res 63(7): 1458–1463.
  57. 57. Siegfried G, Basak A, Benjannet S, Marcinkiewicz SJ, Cromlish JA, et al. (2003) The secretory proprotein convertases furin, PC5 and PC7 activate VEGF-C to induce tumorigenesis. J Clinical Invest 111: 1723–1732.
  58. 58. Siegfried G, Basak A, Prichett-Pejic W, Scamuffa N, Ma L, et al. (2005) Cleavage of PDGF-B at N terminal by proprotein convertases is a prerequisite for its C terminal processing and secretion. Oncogene 24(46): 6925–6935.
  59. 59. Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R, et al. (2003) The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 10(7): 520–526. Erratum in: Nat Struct Biol. 2003 Aug; 10(8):669.
  60. 60. Holyoak T, Kettner CA, Petsko GA, Fuller RS, Ringe D (2004) Structural Basis for Differences in Substrate Selectivity in Kex2 and Furin Protein Convertases. Biochemistry 43: 2412–2421.
  61. 61. Siezen RJ, Creemers JWM, Van de ven WJM (1994) Homology modelling of the catalytic domain of human furin: A model for the eukaryotic subtilisin-like proprotein convertases. Eur J Biochem 222: 255–266.